NCT04349267CompletedPhase 1/2
Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors
A Phase 1/2 Study of BMS-986315 as Monotherapy and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors
Source: ClinicalTrials.gov · Last updated 17 Dec 2025
Brief summary (registry, in English)
The purpose of this study is to evaluate BMS-986315 alone and in combination with nivolumab or cetuximab in participants with advanced solid tumors.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 44 (actual)
- First submitted
- 15 Apr 2020
- Start date
- 14 Jul 2020
- Primary completion date
- 22 Aug 2024
- Lead sponsor
- Bristol-Myers Squibb
- Diseases
- Head and neck cancer, Kidney cancer, Lung cancer
- NCT number
- NCT04349267
What you commit to
- Study type: Interventional · Phase 1/2
- Participants enrolled: 44
- From 14 Jul 2020 to the primary completion date, 22 Aug 2024
- 8 sites in 3 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participants with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications
- Prior participation in anti-natural killer cell receptor (anti-NKG2A) clinical study
Other illness
- Participants with active, known or suspected autoimmune disease
- Uncontrolled or significant cardiovascular disease
- History of or with active interstitial lung disease or pulmonary fibrosis
- History of allergy or hypersensitivity to study drug components
- Other protocol-defined inclusion/exclusion criteria apply
Who the study is looking for
- Participants must have histologic confirmation of advanced (metastatic, recurrent, and/or unresectable) squamous cell carcinoma of the head and neck (SCCHN), nonsmall cell lung cancer (NSCLC), or renal cell cancer (RCC) with measurable disease per RECIST 1.1
- Participants expected to have received standard of care therapies including an available PD-(L)1 inhibitor
- Eastern cooperative oncology group performance status of 0 or 1
- Women of childbearing potential must agree to follow methods of contraception
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (8)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Edmonton | Canada | Unknown status |
| - Coordinator of this site? Confirm its status | Montreal | Canada | Unknown status |
| - Coordinator of this site? Confirm its status | Ottawa | Canada | Unknown status |
| - Coordinator of this site? Confirm its status | Toronto | Canada | Unknown status |
| - Coordinator of this site? Confirm its status | Vancouver | Canada | Unknown status |
| - Coordinator of this site? Confirm its status | Mexico City | Mexico | Unknown status |
| - Coordinator of this site? Confirm its status | Germantown | United States | Unknown status |
| - Coordinator of this site? Confirm its status | Sioux Falls | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.